Featured

Status

All Statuses
  • Completed45

Health Topics

Any Category
Diseases
Neoplasms
Clear Filters

Search Clinical Trials

45 Results
Completed
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
The major objective of this two-stage phase II study is to determine whether tamoxifen is deserving of further study in metastatic bladder cancer. Tamoxifen is expected to function as a …
Completed
Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer
The population selected for this study includes patients with locally advanced and/or poorly differentiated tumors. These patients have an unacceptably high failure rate when treated by radical prostatectomy alone (over …
Baylor Role: Lead Sponsor
Completed
Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
OBJECTIVES: Primary - Evaluate the safety and tolerance of NY-ESO-1/LAGE-1 class-I and class-II vaccine administered subcutaneously in patients with androgen-independent metastatic prostate cancer. Secondary - Compare the response induced by …
Baylor Role: Lead Sponsor
Completed
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
This is a multi-center, non-randomized pharmacokinetically-guided optimal dosing study of intraventricular topotecan in children with neoplastic meningitis. Topotecan will be administered daily for five consecutive days utilizing the schema shown …
Baylor Role: Lead Sponsor
Completed
Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy
The current standard treatment of a large tumor of the balance nerve (acoustic neuroma or vestibular schwannoma) is surgical resection. Complete removal of such tumor is associated with significant risks …
Baylor Role: Collaborator
Completed
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Large clinical trials have confirmed the value of systemic adjuvant therapy in decreasing the risk of recurrence and death in patients with early breast cancer. However, the need to identify …
Baylor Role: Collaborator
Completed
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
Three different doses of CTL will be evaluated: dose level I: 2 x 10e7/m2; dose level II: 5 x 10e7/m2; dose level III: 1 x 10e8/m2 Day 1 YTH 24/54 …
Baylor Role: Lead Sponsor
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role: Lead Sponsor
Completed
Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)
RATIONALE: Camptothecin (CPT) is a plant alkaloid isolated from Camptotheca acuminata in 1966. As a topoisomerase I inhibitor, it has powerful anticancer properties and has been used clinically in the …
Baylor Role: Collaborator
Completed
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
In murine and human xenograft tumor models, administration of PS-341 weekly was associated with significant antitumor activity. In primate studies using a schedule of twice weekly for six weeks, the …
Baylor Role: Lead Sponsor